Aligos Therapeutics shareholders approve ESPP share reserve increase, remove evergreen provision

• Aligos Therapeutics held its annual shareholder meeting on June 25, 2026.
• Shareholders adopted an amendment to the 2020 employee stock purchase plan, adding 500,000 shares to the plan reserve.
• The amendment also removed the plan’s automatic annual share-reserve increases through 2030, fixing the reserve with no further automatic increases.
• Shareholders ratified Ernst & Young as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Shareholders backed an annual schedule for future advisory votes on executive compensation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-285426), on June 26, 2026, and is solely responsible for the information contained therein.